SLC9A1 and cancer: CP, a more potent and specific NHE inhibitor than AM, protects neurons from apoptosis, attenuates glutamate-mediated mitochondrial death pathways, as well as decreases the cellular entry of Ca++ and the mitochondrial overloading of ROS. Thus, NHE1 inhibition may prevent neural necrosis and apoptosis. CP has also been advised to be considered in cancer treatment.